Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $24.72 Average PT from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average rating of “Hold” from the twenty-one ratings firms that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.7222.

Several equities research analysts have recently issued reports on the company. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Piper Sandler cut their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. Finally, Wall Street Zen upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th.

Sarepta Therapeutics Trading Up 6.9%

NASDAQ SRPT opened at $15.88 on Thursday. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $25.32. The firm’s fifty day simple moving average is $16.97 and its 200-day simple moving average is $18.64. The company has a market capitalization of $1.68 billion, a PE ratio of -16.54, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.15 million. During the same quarter last year, the firm earned ($3.42) earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 3.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC raised its holdings in Sarepta Therapeutics by 143.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock worth $2,410,000 after acquiring an additional 62,981 shares during the period. Aberdeen Group plc boosted its holdings in Sarepta Therapeutics by 13.6% during the fourth quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock valued at $48,454,000 after acquiring an additional 268,829 shares during the period. Vanguard Group Inc. boosted its holdings in Sarepta Therapeutics by 9.2% during the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after acquiring an additional 993,283 shares during the period. CWM LLC grew its position in shares of Sarepta Therapeutics by 230.8% in the fourth quarter. CWM LLC now owns 240,536 shares of the biotechnology company’s stock valued at $5,176,000 after purchasing an additional 167,831 shares during the last quarter. Finally, M&T Bank Corp bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $1,794,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.